The above-mentioned studies indicated that these hub genes might exert specific functions in determining response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy and serve as promising biomarkers with potential clinical application in the future, although currently the mechanisms were unclear. This evidence concerns the gene ERBB2 and breast cancer.